Robert Barrow

Linkedin Team icon

Chief Executive Officer and Board Director

Mr. Barrow is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. After joining MindMed as Chief Development Officer in January 2021, he was named CEO in June 2021.

Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona’s development programs. Prior to joining Usona, Mr. Barrow served as Chief Operating Officer of Olatec Therapeutics, LLC, a private, clinical-stage biopharmaceutical company, where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. In addition, he has been responsible for the design and execution of preclinical research programs for new molecular entity drugs in CNS conditions such as multiple sclerosis, Alzheimer’s Disease and Parkinson’s Disease.

Mr. Barrow has also served as both a technical and business adviser to numerous  pharmaceutical organizations ranging from startups to Fortune 500 companies.

Mr. Barrow holds a Masters degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude and is a CFA charterholder.

Paul Summergrad, MD

Professor of Psychiatry and Medicine at Tufts University School of Medicine and Chairman Emeritus of the department of psychiatry at Tufts Medical Center

Nzinga Harrison, MD

Co-Founder & Chief Medical Officer, Eleanor Health

Carol Vallone

Chair of the Board of Directors, Member of Compensation Committee, Member of Audit Committee

Andreas Krebs

Vice Chair of the Board of Directors, Member of Nomination & Governance Committee, Member of Audit Committee

David Gryska

Board Director, Chair of Audit Committee

Roger Crystal, MD

Board Director, Chair of Nomination & Governance Committee, Member of Compensation Committee

Robert Barrow

Chief Executive Officer and Board Director

Suzanne Bruhn, PhD

Board Director, Chair of Compensation Committee, Member of Nomination & Governance Committee

Miri Halperin Wernli, PhD

Executive President

Daniel Karlin, MD, MA

Chief Medical Officer

Mark Sullivan, JD

Chief Legal Officer and Corporate Secretary

Francois Lilienthal, MD, MBA

Chief Commercial Officer

Carrie Liao, CPA

Chief Accounting Officer

Stephanie Fagan, MS

Chief Corporate Affairs Officer

Gregg Pratt, PhD

Chief Regulatory and Quality Assurance Officer

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry at University of Rochester

Maurizio Fava, MD

Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Carole Abel, MBA

VP, Programs and Portfolio Office (PPO)

Peter Mack, PhD

VP, Pharmaceutical Development

Michael Seggev

VP, Global Marketing, Strategic Insights and Digital Innovation

Rafael Muniz, MD

VP, Global Medical Affairs

Phong Duong, PharmD

VP, Global Market Access and Health Economics

Maria Oquendo, MD, PhD

Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania, Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania

Matthias Liechti, MD, PhD

Scientific Collaborator & Advisor

Kim PC Kuypers, PhD

Scientific Collaborator & Advisor

Peter Gasser, MD

Clinical Advisor